The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.
The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果